Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population
Greenwood, Bonnie C.
Alper, Caroline J.
Price, Mylissa K.
Clements, Karen M.
Lenz, Kimberly J.
Jeffrey, Paul L.
UMass Chan AffiliationsCommonwealth Medicine
Clinical Pharmacy Services
Center for Health Policy and Research
HCV genotype 1
Health Services Administration
Health Services Research
Pharmacy and Pharmaceutical Sciences
MetadataShow full item record
AbstractAn evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/27030
Presented at the Academy of Managed Care and Specialty Pharmacy Annual Conference 2017.
Rights© 2017 University of Massachusetts Medical School